摘要
Background: Osteoporosis is a threat to aged people who have excessive osteoclast activation and bone resorption, subsequently causing fracture and even disability. Inhibiting osteoclast differentiation and absorptive functions has become an efficient approach to treat osteoporosis, but osteoclast-targeting inhibitors available clinically remain rare. Kirenol (Kir), a bioactive diterpenoid derived from an antirheumatic Chinese herbal medicine Herba Siegesbeckiae, can treat collagen-induced arthritis in vivo and promote osteoblast differentiation in vitro, while the effects of Kir on osteoclasts are still unclear. @@@ Purpose: We explore the role of Kir on RANKL-induced osteoclastogenesis in vitro and bone loss in vivo. @@@ Methods: The in vitro effects of Kir on osteoclast differentiation, bone resorption and the underlying mechanisms were evaluated with bone marrow-derived macrophages (BMMs). In vivo experiments were performed using an ovariectomy (OVX)-induced osteoporosis model. @@@ Results: We found that Kir remarkably inhibited osteoclast generation and bone resorption in vitro. Mechanistically, Kir significantly inhibited F-actinring formation and repressed RANKL-induced NF-KB p65 activation and pp38, p-ERK and c-Fos expression. Moreover, Kir inhibited both the expression and nuclear translocation of NFATc1. Ca2+ oscillation and caveolin-1 (Cav-1) were also reduced by Kir during osteoclastogenesis in vitro. Consistent with these findings, 2-10 mg/kg Kir attenuated OVX-induced osteoporosis in vivo as evidenced by decreased osteoclast numbers and downregulated Cav-1 and NFATc1 expression. @@@ Conclusions: Kir suppresses osteoclastogenesis and the Cav-1/NFATc1 signaling pathway both in vitro and in vivo and protects against OVX-induced osteoporosis. Our findings reveal Kir as a potential safe oral treatment for osteoporosis.
学科与关键词
- Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 PathwaysWang, Gang; Ma, Chao; Chen, Kai; Wang, Ziyi; Qiu, Heng; Chen, Delong; He, Jianbo; Zhang, Cheng; Guo, Ding; Lai, Boyong; Zhang, Shuangxiao; Huang, Linfeng; Yang, Fan; Yuan, Jinbo; Chen, Leilei*; He, Wei*; Xu, Jiake*Frontiers in Pharmacology, 2022, 12: 810322.被引 13
- A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen SpeciesWong, Puiian; Lv, Zheng; Li, Jinglan; Wei, Qiushi; Xu, LiangLiang*; Fang, Bin*; Luo, Yiwen*; He, Mincong*Oxidative Medicine and Cellular Longevity, 2022, 2022: 5982014.被引 6
- A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen speciesHong, Guoju; Chen, Zhenqiu; Han, Xiaorui; Zhou, Lin; Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming; Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi*Clinical and Translational Medicine, 2021, 11(5): e392.被引 31
